Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Terminated 3Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 15Gastrointestinal 7Genitourinary 6Endocrine 6Tumor-Agnostic 4Head & Neck 3Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2NET 2Thoracic 1Other neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 1Melanoma 1

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Everolimus × Dermatologic × Clear all
NCT01960829 2015-05-01

Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

Peking University Cancer Hospital & Institute

Phase 2 Unknown
60 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡